Kidney Fibrosis Treatment Market Growth Through 2030 Creates New Strategic Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Kidney Fibrosis Treatment Market Value Expansion And Long-Term Growth Outlook
The kidney fibrosis treatment market has experienced robust expansion in recent years, projected to rise from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historic growth is driven by factors such as the increasing incidence of chronic kidney disease, the insufficient efficacy of standard treatments, a greater reliance on ACE inhibitors and ARBs, the escalating healthcare strain associated with renal failure, and the broader availability of nephrology care services.
The kidney fibrosis treatment market is projected to experience robust expansion over the coming years, reaching an estimated value of $8.84 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period is fueled by progress in developing targeted antifibrotic agents, a rising elderly population affected by chronic kidney disease (CKD), the increasing application of precision medicine within nephrology, heightened investment in renal research, and enhanced capabilities for early-stage kidney disease detection. Key trends shaping the forecast period include a heightened emphasis on creating antifibrotic drugs, a growing adoption of combination therapies for CKD, expanding investigations into stem cell and regenerative treatments, the broadening availability of early diagnostic and monitoring technologies, and a surge in clinical trials focused on renal fibrosis pathways.
Download A Free Sample Report For Comprehensive Market Insights:
Kidney Fibrosis Treatment Market Development Factors: Which Trends Are Supporting Demand?
The growth of the kidney fibrosis treatment market is anticipated to be driven forward by the rising incidence of chronic kidney diseases. Chronic kidney disease (CKD) entails a gradual decline in kidney functionality over an extended period, frequently stemming from ailments such as diabetes or hypertension, which lead to the buildup of bodily waste. This escalating prevalence of CKD is predominantly fueled by increasing diabetes rates, a condition that harms kidney blood vessels and compromises their filtration capabilities. Kidney fibrosis treatment benefits CKD sufferers by addressing the scarring of renal tissue, diminishing inflammation, and decelerating kidney damage progression, thereby helping to maintain renal function. As reported in July 2025 by Hamadan University of Medical Sciences, an Iranian academic institution, the worldwide number of new chronic kidney disease diagnoses is expected to reach 25.06 million by 2030. Consequently, the increasing occurrence of chronic kidney diseases is propelling expansion within the kidney fibrosis treatment market.
Kidney Fibrosis Treatment Market Segments: Where Are The Largest Growth Opportunities?
The kidney fibrosis treatment market covered in this report is segmented –
1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types
2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests
3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications
4) By End-User: Clinics, Research Center, Hospitals
Subsegments:
1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril
2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan
3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone
4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors
5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat
6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy
Kidney Fibrosis Treatment Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the kidney fibrosis treatment space are placing emphasis on targeted ileal-release immunomodulatory approaches, including NEFECON, which is an oral delayed-release budesonide capsule designed to deliver the medication precisely to the distal ileum. This mechanism modulates gut-associated B-cells, curbing pathogenic IgA production, and thereby decelerating kidney fibrosis progression in individuals with IgA nephropathy. As an example, Everest Medicines, a biopharmaceutical company based in China, introduced NEFECON in June 2024. This therapy employs an enteric-coated, delayed-release formulation to limit systemic steroid exposure, acts on mucosal B-cells in the gut to tackle the underlying cause of IgA nephropathy, and has been shown to substantially reduce the decline in kidney function.
Kidney Fibrosis Treatment Market Major Participants And Competitive Dynamics
Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc
Access The Complete Kidney Fibrosis Treatment Market Report:
Kidney Fibrosis Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
